Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Pharmacol. 2013 Mar 1;85(5):644-52. doi: 10.1016/j.bcp.2012.10.013. Epub 2012 Oct 24.

Targeting FOXM1 in cancer.

Author information

1
Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.

Abstract

Oncogenic transcription factor FOXM1 is overexpressed in the majority of human cancers. In addition, FOXM1 has been implicated in cell migration, invasion, angiogenesis and metastasis. The important role of FOXM1 in cancer affirms its significance for therapeutic intervention. Current data suggest that targeting FOXM1 in mono- or combination therapy may have promising therapeutic benefits for the treatment of cancer. However, challenges with the delivery of anti-FOXM1 siRNA to tumors and the absence of small molecules, which specifically inhibit FOXM1, are delaying the development of FOXM1 inhibitors as feasible anticancer drugs. In this review, we describe and summarize the efforts that have been made to target FOXM1 in cancer and the consequences of FOXM1 suppression in human cancer cells.

PMID:
23103567
DOI:
10.1016/j.bcp.2012.10.013
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center